$MO

Strahlman Ellen R sold $145K of MO

Strahlman Ellen R sold 2,000 shares of ALTRIA GROUP, INC. (MO) at $72.56 ($0.15M total) on 2026-05-26.

Original reporting
SEC EDGAR · Strahlman Ellen R
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:40 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MO
Neutral
medium confidence
Mentioned
$MO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MONeutralLow
01

Why it matters

Insider selling can be interpreted as mild negative sentiment, but without accompanying company-specific news, it typically does not change valuation drivers.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new fundamental catalyst in the text.

03

What to watch

The article provides only the sale details, not the director’s broader trading history, remaining compensation structure, or whether other insiders sold/bought around the same time.

Relevance 4/10Novelty 3/10Timing: filed 2026-05-28, transaction dated 2026-05-26

Background

The article is an SEC Form 4 insider transaction disclosure for Altria Group, Inc. (MO) by director Strahlman Ellen R.

Company-level read

Ticker impact

$MONeutralMedium confidence
Context

Altria director Strahlman Ellen R sold 2,000 shares in an open-market transaction for about $145,118, per a fresh Form 4 filing.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and small versus normal MO trading flows.

Evidence & confidence

The filing discloses transaction size, price, and that it was not under a pre-arranged 10b5-1 plan, but provides no new operational, financial, or regulatory information.

Market effects

No clear read-through to tobacco sector fundamentals from a single director sale.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan does not necessarily imply negative expectations; sales can be driven by diversification, taxes, or pre-existing personal liquidity needs.

Key entities

  • Altria Group, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Strahlman Ellen R

    Director who sold 2,000 shares at $72.5590 per share.

Related articles

$MOMed

Altria’s Dividend Still Yields 6.5%, But Can Earnings Keep Up?

Altria Group (MO) reported Q2 adjusted EPS of $1.48, below the $1.50 expected, on net revenue of about $6.11B. Net earnings fell 3.4% to $2.3B. Marlboro volume dropped 7.4% and On! fell 4.2%, leading Altria to narrow FY adjusted EPS guidance to $5.61-$5.72. The article cites a $74 valuation target and 6.5% dividend yield.

$PMMedAI 8/10

As FDA approves new marketing for nicotine pouches, some doctors sound alarms

The U.S. FDA authorized marketing of four new flavored nicotine pouch products from brand “on!” and raised the total recently approved to 30. The FDA also previously cleared ZYN for 20 products with a “Modified Risk Tobacco Product” claim. Philip Morris makes ZYN and Altria makes “on!”. Health groups cite youth use and addiction risks; FDA says MRTP status does not mean risk-free.

$MOMedAI 8/10

FDA authorizes 4 new nicotine pouches from Altria

The FDA authorized marketing of four On Plus nicotine pouch products made by Helix Innovations, a subsidiary of Altria. The FDA said the review was under a September pilot program and that the pouches have lower levels of most harmful and potentially harmful constituents versus other oral and smokeless products. Altria reported first-half 2026 net revenues up 1.6% to $11.5 billion.

$MOMedAI 8/10

Altria (MO) Q2 2026 Earnings Call Transcript

Altria (MO) reported Q2 2026 adjusted diluted EPS of $1.48, up 2.8%, and $2.80 for the first half, up 4.9%. Full-year guidance was narrowed to $5.61 to $5.72. Smokeable OCI was $3.0B, up 2.4%, with Marlboro pricing strength. Capital returns included $3.6B dividends and $335M buybacks in H1.

$MOMedAI 8/10

Altria (MO) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Mac Livingston Chief Executive Officer - Salvatore Mancuso Chief Financial Officer - Heather Newman TAKEAWAYS Adjusted Diluted EPS -- $1.48 for the second quarter, representing a 2.8% increase, and $2.80 for the first half, up 4.9%. Full-Year Guidance -- Narrowed to a range of $5.61 to $5.72, representing a growth rate of 3.5% to 5.5% from the 2025 base of $5.42.